A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225077

Enrollment

Registered

2020-02-18

Start date

2020-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Hodgkin's Lymphoma

Interventions

investigational material(s) Generic name etc : RO7082859 INN of investigational material : glofitamab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - CD20 positive B cell NHL that is recurrent or refractory to standard therapy or for which no standard therapy exists. - Pathologically confirmed B cell NHL. - ECOG PS of 0 or 1. - Life expectancy =>12 weeks from the date of enrollment. - Major organ function meets all criteria.

Exclusion criteria

Exclusion criteria: - Pregnant or lactating woman. - Current or previous autoimmune disease. - Positive test result for human immunodeficiency virus antibody, hepatitis B surface antigen, HBs antibody, hepatitis B core antibody, or hepatitis C virus antibody. - Current or previous clinically significant liver disease. - Current central nervous system lymphoma, metastases to the CNS, or meningeal metastases. - History of previous therapy with allogenic hematopoietic stem cell transplantation or solid organ transplantation. - History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or fusion proteins.

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics other other(DLT) NCI CTCAE	—

Secondary

Measure	Time frame
safety efficacy pharmacokinetics other other (ADA) Revised Response Criteria for Malignant Lymphoma	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026